These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36341450)

  • 1. Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis.
    Kou L; Wen Q; Xie X; Chen X; Li J; Li Y
    Front Immunol; 2022; 13():1013186. PubMed ID: 36341450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
    Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
    Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
    Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
    Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
    Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
    Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
    Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
    Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
    Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
    Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
    Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H
    Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy.
    Medina P; Jeffers KD; Trinh VA; Harvey RD
    J Pharm Pract; 2020 Jun; 33(3):338-349. PubMed ID: 31694455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis.
    Shen X; Yang J; Qian G; Sheng M; Wang Y; Li G; Yan J
    Front Oncol; 2024; 14():1391724. PubMed ID: 38826783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
    Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
    Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis.
    Xie R; Wu J; Shang B; Bi X; Cao C; Guan Y; Shi H; Shou J
    Cancer Innov; 2022 Dec; 1(4):293-304. PubMed ID: 38089086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews.
    Kanji S; Morin S; Agtarap K; Purkayastha D; Thabet P; Bosse D; Wang X; Lunny C; Hutton B
    Drugs; 2022 May; 82(7):793-809. PubMed ID: 35416592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
    Park R; Lopes L; Cristancho CR; Riano IM; Saeed A
    Front Oncol; 2020; 10():258. PubMed ID: 32257944
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.